Compare FEAM & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | PYXS |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.6M | 71.6M |
| IPO Year | N/A | N/A |
| Metric | FEAM | PYXS |
|---|---|---|
| Price | $2.04 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $8.13 | $6.75 |
| AVG Volume (30 Days) | ★ 566.6K | 548.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $500.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $0.83 |
| 52 Week High | $7.50 | $5.55 |
| Indicator | FEAM | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 35.20 |
| Support Level | $2.11 | $1.28 |
| Resistance Level | $2.59 | $1.39 |
| Average True Range (ATR) | 0.33 | 0.12 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 13.35 | 11.91 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.